This article describes a nivolumab-induced widespread morphea, a very rare and severe nivolumab adverse effect that clinicians should be aware.
Get full access to this article
View all access options for this article.
References
1.
BaraibarI, MeleroI, Ponz-SarviseM, et al.Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer. Drug Saf, 2019; 42:281–294. doi:.
2.
TerrierB, HumbertS, PretaLH, et al.Risk of scleroderma according to the type of immune checkpoint inhibitors. Autoimmun Rev, 2020; 19(8):102596. doi:.
3.
AcarA, OralogluG, YamanB, et al.Nivolumab-induced plaque morphea in a malign melanoma patient. J Cosmet Dermatol, 2021; 20(8):2645–2647. doi:.
4.
Alegre-SánchezA, Fonda-PascualP, Saceda-CorraloD, et al.Relapse of morphea during nivolumab therapy for lung adenocarcinoma. Actas Dermosifiliogr, 2017; 108(1):69–70. doi:.
5.
Dal BelloG, RosinaP, ColatoC, et al.Nivolumab induced morphea. G Ital Dermatol Venereol, 2020; 155(5):701–702. doi:.
